To study the safety, immunogenicity and pharmacokinetics of two intravenously administered human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1 in humans.Design
Open label clinical phase I trial.Setting
Primary institutional care.Patients
Seven HIV-1-infected healthy volunteers with ≥ 500 × 106CD4 cells/l and ≤ 10 000 HIV-1 RNA copies/ml, not treated with highly active antiretroviral therapy (HAART), entered and finished the study.Interventions
and main outcome measures: Eight separate infusions of the hMAb were administered over a 4-week period (total dose 14 g). The safety was assessed by physical examination, blood chemistry, complete blood cell count and recording adverse events. 2F5 and 2G12 plasma levels were determined prior to and at the end of each infusion and during the follow-up period of 22 weeks.Results
No clinical or laboratory abnormalities were observed throughout the study. The median distribution half-life (t1/2α) of 2F5 and 2G12 was 1.02 (range, 0.77–1.47) days and 2.49 (range, 0.92–4.59) days, respectively. The elimination half-life (t1/2β) was calculated to be 7.94 (range, 3.46–8.31) days for 2F5 and 16.48 (range, 12.84–24.85) days for 2G12. The median plasma concentration immediately after the first infusion was 216 μg/ml (range, 158–409 μg/ml) for 2F5 and 238 μg/ml (range, 197–402 μg/ml) for 2G12. Multiple infusions resulted in maximum plasma concentrations of 374 μg/ml (range, 304–700 μg/ml) and 605 μg/ml (range, 479–897 μg/ml) for 2F5 and 2G12, respectively.Conclusions
This study showed that the hMAb 2F5 and 2G12 are safe and well tolerated by HIV-1-infected subjects.